Last reviewed · How we verify

NCT05100563

Participant(s) With Autism and High Pain Tolerance Treated With High Dose Naltrexone

Completed Last updated 11 May 2022
What this trial tests

trial testing 50 mg naltrexone in Autism Spectrum Disorder in 1 participant. Completed in 24 May 2021.

Timeline
1 October 2018
Primary endpoint
24 May 2021
24 May 2021

Quick facts

Lead sponsorState University of New York - Upstate Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1
Start date1 October 2018
Primary completion24 May 2021
Estimated completion24 May 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

State University of New York - Upstate Medical University

Who can join

Adults 12 to 80, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

High dose naltrexone with response gauged by pain tolerance as measured by the cold pressor test may help treat autism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other State University of New York - Upstate Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05100563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing